Breaking News

Eclipsebio Acquires Terrain Bio

The acquisition allows Eclipsebio to support RNA drug developers earlier in development while continuing to deliver deep sequencing-based validation.

Author Image

By: Charlie Sternberg

Associate Editor

Eclipse Bioinnovations Inc. (Eclipsebio), a provider of sequencing-based analytics for RNA therapeutics, has acquired Terrain Bio, a techbio company specializing in AI/ML RNA design and manufacturing analytics. According to Peter Chu, CEO of Eclipsebio, “This acquisition meaningfully advances our vision for Eclipsebio.” He says, “Terrain Bio’s proven AI design capabilities strongly complement our sequencing-first analytics, allowing us to support RNA drug developers earlier in development whi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters